Blog

The windy city of Chicago, Illinois, is set to host the CHEST: American College of Chest Physicians Annual Meeting from October 19 to October 22, 2025, highlighting innovative research and discussions surrounding pulmonary and critical care specialties. The conference will feature multiple sessions concerning the use of artificial intelligence (AI) in medicine, the use of glucagon-like peptide 1 inhibitors to address issues in sleep medicine, and late-breaking abstracts in its 4-day schedule.

The main conference events kick off on October 19, with the keynote address coming from inspirational speaker Sean Swarner, who has 1 functioning lung after 2 bouts with cancer. The power of pulmonary medicine, allowing those with lower lung function to lead normal lives, highlights the reason that many of the doctors practice: to improve the prognosis for those with major pulmonary challenges. After this demonstration of what progress in pulmonary medicine can do for the average person, the core of the conference will get underway.

New coverage guidelines will be debated on Monday morning, specifically on noninvasive ventilation in chronic obstructive pulmonary disease (COPD). The panel aims to review the National Coverage Determination guidelines, identify challenges that will arise due to the guidelines, and discuss how to implement the guidelines into practice.

AI is a topic of conversation at multiple panels, including at the opening session on Tuesday, October 21, where the use of AI will be discussed in both pulmonary and critical care medicine. Experts on the panel plan to highlight 3 AI applications that are affecting medicine in the pulmonary, critical care, and sleep specialties and teach the audience how to use these AI tools to help documentation and clinical decisions. Ethical challenges and implementation pitfalls of AI will also be covered as the practical use of AI is questioned.

Also on Tuesday, the conference will focus on the past, present, and future of respiratory vaccines. COVID-19 vaccines, influenza, and pneumococcal disease vaccines have previously been shown to be helpful in avoiding unnecessary death due to these viruses, and the future development of vaccines in this space could further reduce morbidity in vulnerable populations. The goal of the panel, according to the description, is to “encourage[e] pulmonary and critical care clinicians to continue their work as advocates of vaccination” by going over current science and recommendations for respiratory vaccines.

The conference’s Wednesday events kick off with a panel about the new federal policies in the US that have changed the priorities affecting multiple areas of health. The National Medical Association will be offering insight into what these changes mean for medical education and research across the country, including highlighting both legislation and executive orders that affect health care and discussing methods of reducing the harm that could come from these actions. Aaron Baugh, MD, and Marilyn Foreman, MD, MS, of UCSF Department of Medicine and Indiana University School of Medicine, respectively, will be the moderators for this panel.

The conference is set to conclude on October 22. After 4 full days of panels, discussions, and abstract presentations, CHEST will draw to a close on Wednesday evening, after providing pulmonologists and other specialists across the country with updated research, information, and guidelines to better serve their patients when they return to their practices.

^{This material (including market commentary, market data, observations or the like) has been prepared by personnel in the Investment Banking Group of JPMorgan Chase & Co. It has not been reviewed, endorsed or otherwise approved by, and is not a work product of, any research department of JPMorgan Chase & Co. and/or its affiliates (“J.P. Morgan”).}

^{Any views or opinions expressed herein are solely those of the individual authors and may differ from the views and opinions expressed by other departments or divisions of J.P. Morgan. This material is for the general information of our clients only and is a “solicitation” only as that term is used within CFTC Rule 1.71 and 23.605 promulgated under the U.S. Commodity Exchange Act.}

^{RESTRICTED DISTRIBUTION: This material is distributed by the relevant J.P. Morgan entities that possess the necessary licenses to distribute the material in the respective countries. This material is proprietary and confidential to J.P. Morgan and is for your personal use only. Any distribution, copy, reprints and/or forward to others is strictly prohibited.}

^{This material is intended merely to highlight market developments and is not intended to be comprehensive and does not constitute investment, legal or tax advice, nor does it constitute an offer or solicitation for the purchase or sale of any financial instrument or a recommendation for any investment product or strategy.}

^{Information contained in this material has been obtained from sources believed to be reliable but no representation or warranty is made by J.P. Morgan as to the quality, completeness, accuracy, fitness for a particular purpose or noninfringement of such information. In no event shall J.P. Morgan be liable (whether in contract, tort, equity or otherwise) for any use by any party of, for any decision made or action taken by any party in reliance upon, or for any inaccuracies or errors in, or omissions from, the information contained herein and such information may not be relied upon by you in evaluating the merits of participating in any transaction. All information contained herein is as of the date referenced and is subject to change without notice. All market statistics are based on announced transactions. Numbers in various tables may not sum due to rounding.}

^{J.P. Morgan may have positions (long or short), effect transactions, or make markets in securities or financial instruments mentioned herein (or options with respect thereto), or provide advice or loans to, or participate in the underwriting or restructuring of the obligations of, issuers mentioned herein. All transactions presented herein are for illustration purposes only. J.P. Morgan does not make representations or warranties as to the legal, tax, credit, or accounting}

^{treatment of any such transactions, or any other effects similar transactions may have on you or your affiliates. You should consult with your own advisors as to such matters.}

^{The use of any third-party trademarks or brand names is for informational purposes only and does not imply an endorsement by JPMorgan Chase & Co. or that such trademark owner has authorized JPMorgan Chase & Co. to promote its products or services.}

^{J.P. Morgan is the marketing name for the investment banking activities of JPMorgan Chase Bank, N.A., J.P. Morgan Securities LLC (member, NYSE), J.P. Morgan Securities plc (authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority), J.P. Morgan SE (Authorised as a credit institution by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB)), J.P. Morgan Securities Australia Limited (ABN 61 003 245 234/AFS Licence No: 238066 and regulated by Australian Securities and Investments Commission) and their investment banking affiliates. J.P. Morgan Securities plc is exempt from the licensing provisions of the Financial and Intermediary Services Act, 2002 (South Africa).}

^{For Brazil: Ombudsman J.P. Morgan: 0800-7700847 / ouvidoria.jp.morgan@jpmorgan.com}

^{For Australia: This material is issued and distributed by J.P. Morgan Securities Australia Limited (ABN 61 003 245 234/ AFS Licence No: 238066) (regulated by ASIC) for the benefit of “wholesale clients” only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this}

^{material must not distribute it to any third party or outside Australia without the prior written consent of J.P. Morgan Securities Australia Limited.}

^{© 2025 JPMorgan Chase & Co. All rights reserved.}